Most people who are suffering from hair loss are always on the lookout for the next revolutionary hair loss cure. One of the ‘breakthrough’ cure that we’ve heard a lot about in 2019 is setipiprant, a drug known for the treatment of asthma.
Setipiprant is an investigational drug developed in 2012 for the treatment of asthma and in 2019 its popularity boosted as a treatment for hair loss. The drug acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is currently being developed as a treatment for male pattern baldness for those who have not had successful results with traditional hair loss medication.
Setipiprant is an antagonist of the prostaglandin D2 receptor 2 (DPD). DPD is responsible for bonding with and responding to certain prostaglandins that are linked to various pathological responses, including those that are linked to allergies, asthma and inflammation.
Research highlighted a link between the PGD2 receptor and hair loss. This receptor is seen at high levels in the scalp of men who are diagnosed with male pattern baldness. It is thought to be caused by a sensitivity to DHT, which is the androgen hormone that attaches to the hair follicles and leads to inflammation and irritation. The irritation caused by DHT can cause hair follicle miniaturization which over time will lead to balding.
PGD2 is produced from PGD2 synthase, an enzyme. PGD2 synthase levels are increased by DHT, with the increase in PGD2 the receptor on the scalp is triggered and this causes inflammation.
The research found that setipiprant stops PGD2 attaching to the receptors and therefore preventing receptor activation which helps battel hair loss.
As with many new medications and cures, Setipiprant is still undergoing numerous research phases and clinic trails and it would be some time until the medication is on offer to the wider audience.